• Pre Clinical And Clinical Research

BioIVT to Provide Rare Biosamples for the FNIH Biomarkers Consortium Neurodegenerative Disease Project

BioIVT is sourcing matched sets of cerebrospinal fluid, serum, and plasma from donors afflicted with ALS to further research of neurofilament in the blood as a biomarker for early stages of neurodegeneration.

PrecisionLife and Sano Genetics announce partnership to accelerate understanding of long COVID and help identify new treatments

A new partnership between PrecisionLife and Sano Genetics will help advance researchers’ understanding of the drivers of long COVID, identifying at-risk patients and potential drug targets.

Discovery Park Ventures launches to drive disruptive innovation & catalyse regional growth

Discovery Park, the Life Sciences Opportunity Zone for ambitious and growing life sciences companies, has launched its investment fund, Discovery Park Ventures (DPV), with stakes in VisusNano and Vitarka Therapeutics.

Exploristics announces global launch of the Spring 2022 release of its clinical trial design platform, KerusCloud.

Exploristics is delighted to announce the launch of the latest release of our revolutionary clinical trial simulation software, KerusCloud Spring 2022. An innovative platform that provides powerful state-of-the-art cloud-based study simulation capabilities to clinical developers of all sizes, KerusCloud tackles the complex challenges involved in designing effective clinical trials.

Member Spotlight: Interview with Simon Chandler, Chief-Executive of Rinri Therapeutics

In light of Deaf Awareness Week, we interviewed Simon Chandler, Chief-Executive of Rinri Therapeutics, a preclinical stage biotechnology company focused on developing advanced regenerative cell therapies for hearing loss.

Rinri Therapeutics accelerates first regenerative cell therapy for hearing loss towards clinic with key senior hires and award of innovation passport

The company’s lead therapeutic candidate, Rincell-1, receives innovative medicine designation under new programme designed to accelerate the drug approval process and improve patient access in the United Kingdom. Rinri appoints Professor Doug Hartley as Chief Medical Officer, and Sheila Casserly as Director of Clinical Operations, to lead the company’s clinical development strategy to support the continued advancement of Rincell-1 towards first-in-human trials.

Cancer Research UK reveals innovation engine underpinned by £400m portfolio of cutting-edge discovery science

Cancer Research UK, the world’s largest independent funder of cancer research, today (Tuesday 26th), unveiled Cancer Research Horizons, its new and ambitious approach to driving innovation in the development of new treatments for patients, by combining the power of academia and industry.

CN Bio introduces PhysioMimix NASH ‘in-a-box’ reagent kit

First product within new ‘in-a-box’ range, which harnesses next-generation, human-relevant Liver-on-a-Chip technology to improve the accuracy and efficiency of NASH drug discovery

NICE reaches important milestone in the UK’s efforts to tackle antimicrobial resistance.

Two new antimicrobial drugs - cefiderocol and ceftazidime–avibactam - are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model after NICE today (Tuesday, 12 April 2022) published draft guidance estimating their value to the NHS.

BioIVT Appoints Jennifer Murphy as Senior Vice President of Global Commercial Operations

Jennifer has more than 16 years’ commercial leadership experience in the diagnostics and life sciences industries.